PL390769A1 - Analog cytozyny, sposób otrzymywania analogu cytozyny, inhibitor DNA metylotransferazy 1, sposób inhibowania metylacji DNA, zastosowanie analogu w leczeniu chorób związanych z odstępstwami od normy metylacji DNA - Google Patents

Analog cytozyny, sposób otrzymywania analogu cytozyny, inhibitor DNA metylotransferazy 1, sposób inhibowania metylacji DNA, zastosowanie analogu w leczeniu chorób związanych z odstępstwami od normy metylacji DNA

Info

Publication number
PL390769A1
PL390769A1 PL390769A PL39076910A PL390769A1 PL 390769 A1 PL390769 A1 PL 390769A1 PL 390769 A PL390769 A PL 390769A PL 39076910 A PL39076910 A PL 39076910A PL 390769 A1 PL390769 A1 PL 390769A1
Authority
PL
Poland
Prior art keywords
dna methylation
cytosine analogue
analog
treatment
dna
Prior art date
Application number
PL390769A
Other languages
English (en)
Other versions
PL229581B1 (pl
Inventor
Jan Barciszewski
Wojciech T. Markiewicz
Ewelina Adamska
Beata Plitta
Małgorzata Giel-Pietraszuk
Eliza Wyszko
Maria Markiewicz
Agnieszka Fedoruk-Wyszomirska
Tadeusz Kuliński
Marcin Chmielewski
Original Assignee
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Chemii Bioorganicznej Polskiej Akademii Nauk filed Critical Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Priority to PL390769A priority Critical patent/PL229581B1/pl
Priority to EP11716084.6A priority patent/EP2556081B1/en
Priority to US13/576,709 priority patent/US9040490B2/en
Priority to PCT/PL2011/000032 priority patent/WO2011115513A2/en
Priority to JP2013500020A priority patent/JP2013522289A/ja
Publication of PL390769A1 publication Critical patent/PL390769A1/pl
Publication of PL229581B1 publication Critical patent/PL229581B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku jest analog cytozyny, sposób otrzymywania analogu cytozyny, inhibitor DNA metylotransferazy 1, sposób inhibowania metylacji DNA, zastosowanie analogu w leczeniu chorób związanych z odstępstwami od normy metylacji DNA. Bardziej szczegółowo wynalazek dotyczy różnych pochodnych cytozyny, a także sposobu otrzymywania mono- i wielo-1,4,5 i 6 podstawionych cytozyny. Ogólnie rozwiązanie dotyczy stworzenia efektywnych modulatorów metylacji DNA, które mogłyby być wykorzystywane przy przeciwdziałaniu oraz leczeniu chorób związanych z zaburzeniami poziomu metylacji DNA.
PL390769A 2010-03-19 2010-03-19 Analog cytozyny i jego zastosowanie w leczeniu chorób związanych z zaburzeniami metylacji DNA PL229581B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL390769A PL229581B1 (pl) 2010-03-19 2010-03-19 Analog cytozyny i jego zastosowanie w leczeniu chorób związanych z zaburzeniami metylacji DNA
EP11716084.6A EP2556081B1 (en) 2010-03-19 2011-03-17 A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
US13/576,709 US9040490B2 (en) 2010-03-19 2011-03-17 Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation
PCT/PL2011/000032 WO2011115513A2 (en) 2010-03-19 2011-03-17 A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation
JP2013500020A JP2013522289A (ja) 2010-03-19 2011-03-17 シトシン類似体、シトシン類似体の調製方法、ｄｎａメチルトランスフェラーゼ１阻害剤、ｄｎａメチル化の阻害方法、正常なｄｎａメチル化からの逸脱と関連する疾患の治療における類似体の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL390769A PL229581B1 (pl) 2010-03-19 2010-03-19 Analog cytozyny i jego zastosowanie w leczeniu chorób związanych z zaburzeniami metylacji DNA

Publications (2)

Publication Number Publication Date
PL390769A1 true PL390769A1 (pl) 2011-09-26
PL229581B1 PL229581B1 (pl) 2018-08-31

Family

ID=44168248

Family Applications (1)

Application Number Title Priority Date Filing Date
PL390769A PL229581B1 (pl) 2010-03-19 2010-03-19 Analog cytozyny i jego zastosowanie w leczeniu chorób związanych z zaburzeniami metylacji DNA

Country Status (5)

Country Link
US (1) US9040490B2 (pl)
EP (1) EP2556081B1 (pl)
JP (1) JP2013522289A (pl)
PL (1) PL229581B1 (pl)
WO (1) WO2011115513A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039860A2 (en) * 2012-09-07 2014-03-13 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating dnmt1 inhibitor activity
US11504369B2 (en) 2019-03-22 2022-11-22 President And Trustees Of Bates College Cytosine-based TET enzyme inhibitors
WO2020197541A1 (en) * 2019-03-22 2020-10-01 President And Trustees Of Bates College Cytosine-based tet enzyme inhibitors
CN116284188B (zh) * 2023-02-07 2024-07-26 南开大学 一种dna甲基转移酶dnmt1的双底物抑制剂及其应用
PL450139A1 (pl) * 2024-10-25 2026-04-27 Instytut Chemii Bioorganicznej Polskiej Akademii Nauk 4-N-furfurylocytozyna i kompozycja ją zawierająca do zastosowań medycznych

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
PL216370B1 (pl) * 2007-11-25 2014-03-31 Inst Chemii Bioorg Pan Sposób otrzymywania 4-N-furfurylocytozyny, kompozycja antystarzeniowa oraz zastosowanie 4-N-furfurylocytozyny do wytwarzania kompozycji antystarzeniowej

Also Published As

Publication number Publication date
WO2011115513A3 (en) 2012-02-23
WO2011115513A9 (en) 2012-05-03
US9040490B2 (en) 2015-05-26
EP2556081B1 (en) 2021-06-16
WO2011115513A2 (en) 2011-09-22
EP2556081A2 (en) 2013-02-13
PL229581B1 (pl) 2018-08-31
JP2013522289A (ja) 2013-06-13
US20120322755A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
IN2014DN09134A (pl)
UA115983C2 (uk) Інгібітори днк-пк
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
TW201613875A (en) EGFR inhibitors, their preparation and their use thereof
SG179418A1 (en) Inhibitors of the hedgehog pathway
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
IN2015DN01156A (pl)
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX336711B (es) Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
IN2015DN01151A (pl)
MX2015010876A (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3).